UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 1-U
CURRENT REPORT PURSUANT TO REGULATION A
Date of Report (Date of earliest event reported): April 28, 2023
Emerald Health Pharmaceuticals Inc.
(Exact name of issuer as specified in its charter)
Delaware
State or other jurisdiction of incorporation or organization
82-0669961
(I.R.S. Employer Identification No.)
5910 Pacific Center Blvd., Suite 320, San Diego, CA 92121
(Full mailing address of principal executive offices)
(858) 352 - 0622
(Issuer’s telephone number, including area code)
Common stock, par value $0.0001
(Title of each class of securities issued pursuant to Regulation A)
Item 9. Other Events
As previously disclosed, on March 17, 2023, Emerald Health Therapeutics, Inc. (the “Company”) filed a certificate of dissolution with the Delaware secretary of state and officially dissolved. The Company is in the process of winding down and liquidating pursuant to the Plan of Liquidation and Dissolution (“Plan”) approved by the Company’s Board of Directors and the Company’s stockholders.
Attached as Exhibit 99.1 to this Form 1-U is a report providing information on the Company’s wind-down and liquidation process, including certain unaudited financial information for the year ended December 31, 2021.
1
Exhibit Index
| Exhibit No. | Description of Exhibit | |
| 99.1 | Company Update |
2
SIGNATURES
Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| EMERALD HEALTH PHARMACEUTICALS INC., | ||
| a Delaware corporation | ||
| By: | /s/ Joe Lugo | |
| Joe Lugo | ||
| Interim Principal Executive Officer | ||
Date: April 28, 2023
3
